I believe it was stated in the mist recent update that many factors could slow the rate of enrollment.
The screening process involves finding patients hospitalized and using oxygen. So the process is limited to specific conditions.
It was also stated that many patients are showing up to the hospital at an advanced stage of infection, past the point of receiving the doses by pill.
At some point, with positive data, the company (or whichever Big Pharma company that has licensing rights/ownership) will finish the work started on an intravenous form of Ifenprodil.
One other tidbit from the update.. Chris mentioned the potential of a backlog of recording data from each patient, and how intensive that collection process is. Also mentioned how the doctor's control the study, not the company.
Food for thought...In my opinion only.
Patience has always been, and remains, the best modus operandi to follow here at Algernon.
But besides that, the company and especially Chris and Mark, the 2-Man Wrecking Crew of hitting milestones and deadlines...so far... shouldn't be 2nd guessed and Monday Morning Quarterbacked just yet.
The damn game is only getting started.
And to borrow a term that is needed here to finish up...Sheesh!
Good Luck and keep your head up! The punches never stop comin around here.
But like The Greatest... the Rope-a-dope strategy has worked before. We're not out of this fight one bit!
Algernon Boom By Yay!
LS5
LS5